The professional group of the brachytherapy and the minimally invasive therapy in oncology

In 2001, the first case of transrectal ultrasound-guided radioactive seed implantation therapy for the prostate cancer in China was completed in the Peking University Third Hospital, which opened a new era of the radioactive seed therapy in China. After that, all kinds of imaging technologies have been comprehensively and systematically introduced into the field of seed implantation therapy, greatly improving the therapeutic effect of tumors. Subsequently, Professor Wang Junjie, the director of the Department of Radiation Therapy, established the Radiation Seed Implantation Therapy Group of the China Anti-Cancer Association to promote the healthy and orderly development of seed implantation therapy. In 2009, Professor Wang Junjie proposed the concept of image-guided interstitial brachytherapy. The results of the clinical study about the radioactive seed implantation therapy of our Department are quoted in NCCN guidelines. In 2015, the team of Professor Wang Junjie took use of the 3D printing technology to design individualized templates to further improve the accuracy of seed implantation treatment, so that the seed implantation in specific cases can achieve almost the same curative effect as the surgical resection. At the same time, it has resolved the problem that the flat template technology can only be used for prostate cancer treatment for many years, laying a solid foundation for seed implantation treatment which could be widely used in head and neck, chest, abdomen and pelvis carcinoma. The 3D printed template-assisted seed implantation therapy indicates that the radioactive seed implantation therapy has entered the new era of the precision therapy. Our research results are cited in many domestic and international guidelines. In addition to the seed implantation, our department relies on the image guidance technology and the computer navigation technologyto carries out the CT-guided- biopsy for the various organs and tissues and the ablation for the malignant tumor.

From 2017 to 2019, Professor Wang Junjie led his team to formulate7 treatment standard / consensus, including the CT-guided radioactive seed implantation, the 3D printed template-assisted radioactive seed implantation, the radioactive seed implantation treatment for head and neck tumors, lung cancer, etc. As an affiliated hospital of Peking University, our department not only relieves patients' pain, but also undertakes the responsibility of training and promotion of the standard radioactive seed implantation treatment. In 2017, it became the first batch of training centers for radioactive seed therapy by Beijing Municipal Health and Family Planning Commission. In 2019, it became the first batch of radioactive seed training base of the Chinese Medical Doctor Association. In 2017, the radioactive seed implantation work of our department went further internationally, and delivered speeches at the annual meeting of ABS and the American Nuclear Medicine Conference for many years. At the same time, many European and American patients came to our department for this treatment. In 2019, Professor Wang Junjie visited and exchanged the concept of the radioactive seed implantation treatment with Vietnam specialist for many times to contribute to the country's Belt and Road strategy. After years of efforts, the tumor minimally invasive treatment and short-range treatment professional group led by Professor Wang Junjie has received support from a number of funds, such as the Capital Development Fund, the National Natural Science Foundation, the National Ministry of Science and Technology Key R & D Program, etc.